

**PRODUCT INFORMATION**

|   |  |
|---|--|
| <b>Common Name</b>                      | MEDI-551,Medi-551  |
| <b>Conjugate</b>                        | PE-conjugated  |
| <b>Synonyms</b>                         | CD19;4;VID3;GC12802  |
| <b>Applications</b>                     | Flow Cyt   |
| <b>Endotoxin</b>                        | Less than 1.0 EU/ $\mu$ g by the LAL method. For <1 EU/mg requirements, please contact us for customization.                                   |
| <b>Recommended Dilutions</b>            | Flow Cyt 1:100   |
| <b>Formulation &amp; Reconstitution</b> | Liquid PBS with 0.05% Proclin300, 1% BSA   |
| <b>Host Species</b>                     | Humanized  |
| <b>IgG type</b>                         | Human IgG1 - kappa   |
| <b>Reactivity</b>                       | Human  |
| <b>Target</b>                           | CD19   |
| <b>Uniprot ID</b>                       | P15391   |
| <b>Description</b>                      | PE-conjugated Anti-CD19 (inebilizumab biosimilar)mAb   |
| <b>Delivery</b>                         | Under Development  |
| <b>Storage&amp;Shipping</b>             | Store at 2°C-8°C for 6 months  |
| <b>Sterility</b>                        | Products are supplied non-sterile. For cell culture applications, dilute in appropriate medium and sterile-filter (0.22 $\mu$ m) prior to use. |
| <b>Background</b>                       | Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.  |
| <b>Usage</b>                            | Research use only  |

